Register entry
- Registered sites
- 0
- Active NDC listings
- 1
- Live patents
- 5
- Exclusivities
- 1
- Countries
- 0
Exclusivity
Patents and exclusivities
5| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 10294474 | REDEMPLOplozasiran sodium | substance, product | Mar 2037 |
| 11174481 | REDEMPLOplozasiran sodium | substance, product | Mar 2037 |
| 10597657 | REDEMPLOplozasiran sodium | substance, product | Sept 2038 |
| 11214801 | REDEMPLOplozasiran sodium | substance, product | Sept 2038 |
| 12365899 | REDEMPLOplozasiran sodium | substance, product | Sept 2038 |
| Product | Exclusivity | Until |
|---|---|---|
| REDEMPLOPLOZASIRAN SODIUM | ODE-541 Orphan drug | Nov 2032 |
Catalogue
Marketed products
1| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| REDEMPLO | plozasiran | injection, solution, subcutaneous | 84141-025NDA |
Enquiry
Common questions
- Is Arrowhead Pharmaceuticals, Inc. FDA approved?
- Arrowhead Pharmaceuticals, Inc. holds no registered establishment of its own; 1 drug product is listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Arrowhead Pharmaceuticals, Inc. make?
- 1 product is listed under Arrowhead Pharmaceuticals, Inc. in the openFDA NDC Directory, most often as injection, solution. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.